CXCR2-IN-1 - CXCR 抑制劑 - 生命科學試劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemECXCR2-IN-1Cat. No.: HY-101022CAS No.: 1873376-49-8分式: CHClFNOS分量: 476.35作靶點: CXCR作通路: GPCR/G Protein; Immunology/Inflammation儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 5.4 mg/mL (11.34

2、 mM; Need ultrasonic and warming)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.0993 mL 10.4965 mL 20.9930 mL5 mM 0.4199 mL 2.0993 mL 4.1986 mL10 mM 0.2099 mL 1.0496 mL 2.0993 mL請根據(jù)產品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 CXCR2-IN-1是可滲透中樞神經系統(tǒng)的CXCR2拮抗劑，pIC50值為9.3。IC50 & T

3、arget CXCR29.3 (pIC50)體外研究 CXCR2 plays an important role in the activation and recruitment of neutrophils to sites of inflammation.CXCR2-IN-1 shows favorable central nervous system penetration property (Br/Bl0.45) 1.1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE體內研究 CXCR2-IN-1 shows efficacy in a

4、 cuprizone-induced demyelination model through oral administration,providing evidence to support CXCR2 to be a potential therapeutic target to treat demyelinating diseasessuch as multiple sclerosis 1.PROTOCOLAnimal Mice: Mice are fed with cuprizone for 5 weeks to cause demyelinating lesions in the C

5、NS and then orallyAdministration 1 administrated with CXCR2-IN-1 for 9 consecutive days at doses of 30 and 100 mg/kg twice daily 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Xu H, et al. Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders. ACS MedChem Lett. 2016 Feb 8;7(4):397-402.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792